RCBTB2

Across TCGA pan-cancer cohorts, RCBTB2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RCBTB2 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher RCBTB2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RCBTB2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

CESC, UCEC, and BLCA are the cancer types where RCBTB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.261	0.798	.006	12	view →
UCEC	DFS	Median	All	0.955	0.619	.018	6	view →
BLCA	DFS	Median	III,IV	1.000	0.269	.035	3	view →
LUAD	OS	Median	II,III,IV	0.236	0.709	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RCBTB2–CESC (OS)

Open the CESC breakdown →